The combined use of sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists may offer notable benefits for optimizing cardiovascular and renal outcomes...
Brendon Neuen, MBBS, PhD Credit: X.com Findings from a recent study are providing support for the combined use of sodium-glucose transport protein 2 (SGLT2) inhibitors and...